Drug Profile
Tyroserleutide - Shenzhen Kangzhe Pharmaceutical
Alternative Names: CMS-024; YSLLatest Information Update: 09 Mar 2022
Price :
$50
*
At a glance
- Originator China Medical System
- Class Antineoplastics; Oligopeptides
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Apoptosis stimulants; Intercellular adhesion molecule 1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Liver cancer
Most Recent Events
- 09 Mar 2022 Discontinued - Phase-III for Liver cancer (Combination therapy) in China (IV)
- 19 Jan 2012 Tyroserleutide is available for licensing as of 31 Dec 2010. http://en.cms.net.cn/
- 31 Jul 2011 Phase-III clinical trials in liver cancer (Combination therapy) in China (IV, Infusion) (NCT01489566)